AbSci (NASDAQ:ABSI) Rockets 12.78% as AI-Designed Antibody Shows Preclinical Hair Growth Potential

Absci (NASDAQ:ABSI) surged 12.78% in pre-market trading on December 11, 2025, driven by promising preclinical data for its AI-designed antibody ABS-201.

The compound demonstrated potential to stimulate hair growth by inhibiting prolactin receptor (PRLR) signaling, extending the anagen (growth) phase of hair follicles, and preserving stem cell populations in human ex vivo studies. These findings, presented at a Key Opinion Leader seminar, highlight ABS-201’s ability to address unmet needs in androgenetic alopecia treatment, where current options like minoxidil and finasteride offer limited efficacy and notable side effects.

ABS-201’s mechanism targets follicular miniaturization, a key driver of pattern hair loss, by promoting vellus-to-terminal hair regeneration. The data suggest it could offer a disease-modifying approach distinct from existing therapies, with an interim Phase 1/2a trial readout anticipated in late 2026.

The stock’s recent momentum reflects growing confidence in the program’s potential to redefine hair loss treatment.